Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration

Retina

Volumn 32, Issue 5, 2012, Pages 956-966

  Park, Susanna S ^a   Daftari, Inder ^b   Phillips, Theodore ^b   Morse, Lawrence S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

age related macular degeneration; anti VEGF therapy; choroidal neovascularization; combination therapy; exudative age related macular degeneration; neovascular age related macular degeneration; proton beam irradiation; radiation; radiotherapy; ranibizumab

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CILIARY BODY; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; EYE; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; IMAGING SYSTEM; IRRADIATION; LENS; MALE; MEDICAL INSTRUMENTATION; MONOTHERAPY; OBSERVATIONAL STUDY; OPTIC DISK; OPTIC NERVE; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL (TOPIC); PILOT STUDY; PROSPECTIVE STUDY; PROTON RADIATION; RADIATION DOSE; RETINA; RETINA MACULA AGE RELATED DEGENERATION; STEREOTACTIC TREATMENT; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; X RAY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; PROTONS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, HIGH-ENERGY; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84860838649     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31822a8d6a     Document Type: Article

References (28)

1. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572. (Pubitemid 38456293)
2. Rein DB, Wittenborn JS, Zhang X, et al. Forecasting age-related macular degeneration through the year 2050. Arch Ophthalmol 2009;127:533-540.
3. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-1642. (Pubitemid 15204559)
4. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444. (Pubitemid 44511558)
5. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431. (Pubitemid 44511557)
6. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1991;112:642-656.
7. Silvagnanavel V, Evans JR, Ockrim Z, Chong V. Radiotherapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2004;4:CD004004.
8. Hori K, Saito S, Tamai M. Effect of irradiation on neo-vascularization in rat skinfold chambers: implications for clinical trials of low-dose radiotherapy for wet-type age-related macular degeneration. Int J Radiat Oncol Biol Phys 2004;60: 1564-1571.
9. Hess C, Vuong V, Hegyl I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumor growth. Br J Cancer 2001;85: 2010-2016. (Pubitemid 34775341)
10. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29: 3-9.
11. Avila MP, Farah ME, Santos A, et al. Twelve-month short-term safety and visual acuity results from a multicentre, prospective study of epiretinal strontium-90 brachytherapy with bevaci-zumab for the treatment of subfoveal choroidal neovascula-rization secondary to age-related macular degeneration. Br J Ophthalmol 2009;93:305-309.
12. Yonemoto LT, Slater JD, Blacharski P, et al. Dose response in the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: results of a phase I/II dose-escalation study using proton beam radiotherapy. J Radiosurg 2000;3:47-54.
13. Zambarakji HJ, Lane AM, Ezra E, et al. Proton beam irradiation for neovascular age-related macular degeneration. Ophthalmology 2006;113:2012-2019. (Pubitemid 44635705)
14. Ciulla TA, Danis RP, Klein SB, et al. Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. Am J Ophthalmol 2002;134: 905-906. (Pubitemid 35425461)
15. Daftari IK, Renner TR, Verhey LJ, et al. New UCSF proton ocular beam facility at the Crocker Nuclear Laboratory Cyclotron (UC Davis). Nucl Inst Meth Phys Res 1996;A380: 597-612. (Pubitemid 126390092)
16. Sheen MA. Development of the EYE Proton Therapy Planning Program. PTCOG Meeting, Chester, England; May 16-18, 1994: 29.
17. Trikha R, Morse LS, Zawadzki RJ, et al. Ten-year follow-up of eyes treated with stereotactic-fractionated external beam radiation for neovascular age-related macular degeneration. Retina. In press.
18. Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2010. Epub ahead of print.
19. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable-dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
20. Robison CD, Krebs I, Binder S, et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration. Am J Ophthalmol 2009;148:79-82.
21. Moshfeghi DM, Kaiser PK, Gertner M. Stereotactic low-voltage X-ray irradiation for age-related macular degeneration. Br J Ophthalmol. 2010. Epub ahead of print.
22. Hanlon J, Lee C, Chell E, et al. Kilovoltage stereotactic radiosurgery for age-related macular degeneration: assessment of optic nerve dose and patient effective dose. Med Phys 2009; 36:3671-3681.
23. Cohen M, Jones D, Greene D. Central axis depth dose data for use in radiotherapy. Br J Radiol 1972;11:8-17.
24. Flaxel CJ. Use of radiation in the treatment of age-related macular degeneration. Ophthalmol Clin N Am 2002;15: 437-444. (Pubitemid 36076598)
25. Guyer DR, Mukai S, Egan KM, et al. Radiation maculopathy following proton beam irradiation for choroidal melanoma. Ophthalmology 1992;99:1278-1285.
26. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 2008;70:974-977. (Pubitemid 351296131)
27. Avci B, Avci R, Inan UU, Kaderli B. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci 2009;50: 3438-3446.
28. Storkebaum E, Carmeliet P. VEGF: a critical player in neurodegeneration. J Clin Invest 2004;113:14-18. (Pubitemid 38541624)